You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Therapeutic Antibodies for Biofilm Infections

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Use of EF2K inhibitors to inhibit tumor growth and sensitize cancer cells to existing chemotherapy treatment

    SBC: LONGEVICA PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Eukaryotic elongation factor protein kinase eEF K is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an andquot atypicalandquot kinase domain Our recent findings demonstrate that inhibition or genetic inactivation of eEF K protects normal tissues from cytotoxic effects of ionizing radiation and chemotherapeutic ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Novel sigma-2 receptor modulators for the treatment of cognitive dysfunction

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION provided by applicant Cognition Therapeutics Inc andapos s mission is to develop effective therapeutics for Alzheimerandapos s disease AD Recent scientific discoveries have identified oligomers of the brain protein A as toxic culprits in disease progression Cognition in partnership with Temple University has identified a novel series of sigma receptor binding modulators t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Enhancing Care of the Aged and Dying in Prisons

    SBC: KLEIN BUENDEL, INC.            Topic: NIA

    DESCRIPTION provided by applicant The United States has the highest rate of incarceration in the world The demographics of the prison population are shifting In fact the number of sentenced state and federal prisoners age or older grew at times the rate of the overall prison population from The health status of aging inmates does not mirror the free world population In fac ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Therapeutics to Treat Candida albicans Biofilm Infections

    SBC: BIOSYNESIS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government